https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2014-10-15 / Mol Med Rep 2015 Jan;11(1):317-26
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2014-10-15 / Mol Med Rep 2015 Jan;11(1):317-262014-10-15 00:00:002014-10-15 00:00:00Apoptotic induction of lung adenocarcinoma A549 cells infected by recombinant RVG Newcastle disease virus (rL-RVG) in vitro
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2014-10-15 / Mol Med Rep 2015 Jan;11(1):327-32
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2014-10-15 / Mol Med Rep 2015 Jan;11(1):327-322014-10-15 00:00:002019-02-15 09:18:18Inhibition of cell proliferation by mild hyperthermia at 43˚C with Paris Saponin I in the lung adenocarcinoma cell line PC-9
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2014-09-28 / Cancer Immunol. Immunother. 2015 Jan;64(1):51-9
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2014-09-28 / Cancer Immunol. Immunother. 2015 Jan;64(1):51-92014-09-28 00:00:002019-02-15 08:45:30Randomized controlled phase III trial of adjuvant chemo-immunotherapy with activated killer T cells and dendritic cells in patients with resected primary lung cancer
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2014-09-25 / Oncol Lett 2014 Dec;8(6):2569-2576
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2014-09-25 / Oncol Lett 2014 Dec;8(6):2569-25762014-09-25 00:00:002014-09-25 00:00:00Effect of recombinant Newcastle disease virus transfection on lung adenocarcinoma A549 cells
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2014-07-30 / BMC Cancer 2014 Jul;14:551
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2014-07-30 / BMC Cancer 2014 Jul;14:5512014-07-30 00:00:002014-07-30 00:00:00Pharmacological modulation of autophagy enhances Newcastle disease virus-mediated oncolysis in drug-resistant lung cancer cells
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2014-06-01 / J Clin Oncol 32:5s, 2014 (suppl; abstr 3062)
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2014-06-01 / J Clin Oncol 32:5s, 2014 (suppl; abstr 3062)2014-06-01 00:00:002014-06-01 00:00:00γδ T cells in combination with Newcastle disease virus and dendritic cell therapy as a novel immunotherapeutic approach in treating of advanced lung cancer.
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2014-05-12 / Virol. J. 2014 May;11:84
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2014-05-12 / Virol. J. 2014 May;11:842014-05-12 00:00:002014-05-12 00:00:00Oncolytic therapy of a recombinant Newcastle disease virus D90 strain for lung cancer
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2014-04-10 / Korean J Thorac Cardiovasc Surg 2014 Apr;47(2):77-93
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2014-04-10 / Korean J Thorac Cardiovasc Surg 2014 Apr;47(2):77-932014-04-10 00:00:002019-02-15 08:35:16Current status of oncothermia therapy for lung cancer
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2014-02-01 / Transl Lung Cancer Res 2014 Feb;3(1):53-63
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2014-02-01 / Transl Lung Cancer Res 2014 Feb;3(1):53-632014-02-01 00:00:002019-02-15 08:35:18Immunotherapy in lung cancer
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2014-02-01 / Transl Lung Cancer Res 2014 Feb;3(1):34-45
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2014-02-01 / Transl Lung Cancer Res 2014 Feb;3(1):34-452014-02-01 00:00:002014-02-01 00:00:00Immunotherapy prospects in the treatment of lung cancer and mesothelioma
